Compare Natco Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA JUBILANT LIFE SCIENCES NATCO PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 15.5 13.6 114.1% View Chart
P/BV x 3.0 1.6 191.8% View Chart
Dividend Yield % 1.5 0.9 155.9%  

Financials

 NATCO PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
JUBILANT LIFE SCIENCES
Mar-19
NATCO PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,080898 120.3%   
Low Rs671618 108.7%   
Sales per share (Unadj.) Rs592.1572.0 103.5%  
Earnings per share (Unadj.) Rs188.436.2 520.1%  
Cash flow per share (Unadj.) Rs206.359.5 346.7%  
Dividends per share (Unadj.) Rs8.254.50 183.3%  
Dividend yield (eoy) %0.90.6 158.6%  
Book value per share (Unadj.) Rs833.6301.9 276.1%  
Shares outstanding (eoy) m36.90159.28 23.2%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x1.51.3 111.6%   
Avg P/E ratio x4.620.9 22.2%  
P/CF ratio (eoy) x4.212.7 33.3%  
Price / Book Value ratio x1.12.5 41.9%  
Dividend payout %4.412.4 35.3%   
Avg Mkt Cap Rs m32,311120,694 26.8%   
No. of employees `0004.82.4 202.1%   
Total wages/salary Rs m3,25619,260 16.9%   
Avg. sales/employee Rs Th4,522.538,120.6 11.9%   
Avg. wages/employee Rs Th674.08,058.4 8.4%   
Avg. net profit/employee Rs Th1,439.02,414.3 59.6%   
INCOME DATA
Net Sales Rs m21,84891,108 24.0%  
Other income Rs m404357 113.0%   
Total revenues Rs m22,25291,466 24.3%   
Gross profit Rs m9,28417,390 53.4%  
Depreciation Rs m6623,709 17.8%   
Interest Rs m1542,198 7.0%   
Profit before tax Rs m8,87211,840 74.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m1,9203,268 58.8%   
Profit after tax Rs m6,9525,770 120.5%  
Gross profit margin %42.519.1 222.6%  
Effective tax rate %21.627.6 78.4%   
Net profit margin %31.86.3 502.4%  
BALANCE SHEET DATA
Current assets Rs m21,30745,848 46.5%   
Current liabilities Rs m5,92020,897 28.3%   
Net working cap to sales %70.427.4 257.2%  
Current ratio x3.62.2 164.0%  
Inventory Days Days7357 129.0%  
Debtors Days Days10751 209.1%  
Net fixed assets Rs m14,98665,498 22.9%   
Share capital Rs m369159 231.6%   
"Free" reserves Rs m30,35347,930 63.3%   
Net worth Rs m30,76048,089 64.0%   
Long term debt Rs m042,429 0.0%   
Total assets Rs m37,151114,685 32.4%  
Interest coverage x58.66.4 917.7%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.60.8 74.0%   
Return on assets %19.16.9 275.3%  
Return on equity %22.612.0 188.4%  
Return on capital %29.312.4 236.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32212,422 83.1%   
Fx outflow Rs m2,97817,227 17.3%   
Net fx Rs m7,343-4,805 -152.8%   
CASH FLOW
From Operations Rs m4,63611,215 41.3%  
From Investments Rs m-11,155-10,118 110.2%  
From Financial Activity Rs m6,5096,574 99.0%  
Net Cashflow Rs m-187,612 -0.2%  

Share Holding

Indian Promoters % 52.0 45.6 114.1%  
Foreign collaborators % 1.5 3.5 42.0%  
Indian inst/Mut Fund % 7.8 8.7 90.1%  
FIIs % 16.6 21.2 78.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 21.1 123.2%  
Shareholders   25,395 23,815 106.6%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   WYETH LTD  IPCA LABS  ALKEM LABORATORIES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 93 Points Higher; Oil & Gas and Realty Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the oil & gas sector.

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Oct 16, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - TTK HEALTHCARE COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS